Navigation Links
Biological therapy with cediranib improves survival in women with recurrent ovarian cancer
Date:9/30/2013

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress (ECC2013) [1].

Cediranib, which is taken in pill form, is an inhibitor of a cell signalling process involved in formation of tumour blood vessels, essential for tumour growth, and it is the first oral inhibitor of its kind to show an improvement in the time before patients' disease progresses and in overall survival. The drug is a tyrosine kinase inhibitor, a type of biological therapy that blocks vascular endothelial growth factor (VEGF) receptors, which control the development of blood vessels required for growing tumours.

Professor Jonathan Ledermann, Professor of Medical Oncology at UCL Cancer Institute, University College London, presented first results from ICON6, an international randomised, double-blind, academic clinical phase III trial of cediranib.

"In women whose ovarian cancer had been treated with platinum-based chemotherapy together with cediranib given during and after the chemotherapy, we found that the time before the tumour started to grow again was extended by an average of 3.2 months. This sounds like a modest increase but represents about a 30% improvement, with overall survival also increased by a similar amount, to an average of 2.7 months over a two-year period of follow-up," he said.

Studies with chemotherapy alone have shown that the time before patients experience disease progression following treatment for a relapse that is sensitive to platinum-based chemotherapy is an average of eight to nine months. These latest results show that cediranib in addition to chemotherapy increased the time before the disease progressed from 9.4 to 12.6 months over a period of two years, and it extended overall survival from 17.6 to 20.3 months.

"These are ground-brea
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Religious leaders can be key to biological diversity
2. Single-cell transfection tool enables added control for biological studies
3. Biological activity alters the ability of sea spray to seed clouds
4. Epigenetic changes shed light on biological mechanism of autism
5. PeerJ launches PeerJ PrePrints -- a preprint server for the biological and medical sciences
6. Declaring a truce with our microbiological frienemies
7. UMass Amherst researchers reveal mechanism of novel biological electron transfer
8. Biological wires carry electricity thanks to special amino acids
9. Wayne State University researchers techniques enable more, faster testing of biological liquids
10. Snooze button on biological clocks improves cell adaptability
11. Advance promises to expand biological control of crop pests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/15/2014)...  While we may still be a few years away ... Trek" to gain instant access to all that ailed his ... and tablets for monitoring and measuring our health are cropping ... seem a tad Orwellian to some, but a new survey ... technological opportunities into their healthcare regime. These are ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... 2011 - Genomatix is among the 41 partners of ... as a high impact project within its seventh framework ... data analysis and the development of an intuitive GUI ... within and outside the consortium. "To be part ...
... Bickford from the Department of Biological Sciences at the NUS ... in a recent study, provided compelling evidence from scientific literature ... for many different species all over the world. ... had far-reaching effects on the body size of a wide ...
... discovered that a gene known as an androgen receptor (AR) ... opposite effects on these diseases. In prostate cancer, the AR ... breast cancer, the AR gene promotes cancer growth when the gene ... AR production ceases in women. What this means is that ...
Cached Biology News:Study shows unexpected effect of climate change on body size for many different species 2Researchers discover that same gene has opposite effects in prostate, breast cancers 2
(Date:11/26/2014)... The announced sales of three healthcare units ... to expand in non-healthcare areas, says Kalorama Information. Siemens ... firm says that  Siemens is the third largest company ... the IVD market , with 5.5 billion in IVD ... would likely affect IVD market shares.  ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... announced today that applications for AccelerateBaltimore™ (AB) 2015 ... you have a big idea?,” asked ETC’s President ... about it. AccelerateBaltimore helps you and your big ... 13 weeks.” Interested game changers with “big ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Silicon Valley ... forces with RPM Alliance , provider of clinical ... companies. With the latest addition to its CRO Partnership ... validated EDC system to India. , “We have ... robust and customizable EDC platform which is both user ...
(Date:11/26/2014)... November 25, 2014 Miles Holder, formerly ... the Graphel Carbon Products team as Sales/Marketing Manager. Mr. ... and customer service for the graphite industry. , “We ... our team,” stated Dave Trinkley, VP of Market and ... range of experience in the graphite industry, along with ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2
... Consistent,Electronic Health Record for All Citizens Using City ... GREAT RIVER, N.Y., Oct. 16 Netsmart Technologies, ... for health and,human services organizations, today announced it ... contract by the City and County of San,Francisco, ...
... access to advanced gene-sequencing,technologies and gives new hope ... 16 Swedish Neuroscience,Institute (SNI) today announced that ... Hill Campus, the Center for Advanced Brain Tumor,Treatment ... patients diagnosed,with both benign and malignant brain tumors. ...
... Phase 3 CAPACITY Program - ... rate in CAPACITY -, BRISBANE, Calif., Oct. 16 ... 16, 2008, the Japanese,Ministry of Health, Labor and Welfare (MHLW) ... Ltd. to market pirfenidone,for the treatment of patients with idiopathic ...
Cached Biology Technology:Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 2Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 2Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 4InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4
... Klenow fragment is a proteolytic ... DNA Polymerase I which ... 5 exonuclease activity, but has ... Klenow retains the polymerization fidelity ...
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
Biology Products: